Denosumab/nivolumabGrade 2 immune-related rheumatological toxicity and hypopituitarism: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1891卷 / 1期

关键词：

D O I：

10.1007/s40278-022-09370-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：118 / 118

相关论文

共 50 条

[1] NivolumabGrade 3 immune-related hepatitis: case report
[J]. Reactions Weekly, 2018, 1709 (1) : 185 - 185
[2] AntineoplasticsLack of efficacy, immune-related hyperthermia and immune-related pneumonitis: case report
[J]. Reactions Weekly, 2021, 1864 (1) : 43 - 43
[3] Camrelizumab/catequentinibGrade 2 immune-related pneumonia: case report
[J]. Reactions Weekly, 2022, 1903 (1) : 106 - 106
[4] NivolumabSymptomatic immune-related pancreatitis: case report
[J]. Reactions Weekly, 2016, 1615 (1) : 150 - 150
[5] PembrolizumabFocal immune-related pancreatitis: case report
[J]. Reactions Weekly, 2018, 1704 (1) : 300 - 300
[6] PembrolizumabAcquired immune-related pneumonitis : case report
[J]. Reactions Weekly, 2021, 1864 (1) : 320 - 320
[7] PembrolizumabSevere immune-related hepatitis: case report
[J]. Reactions Weekly, 2020, 1788 (1) : 191 - 191
[8] PembrolizumabImmune-related pneumonitis and immune-related polyneuropathy: 2 case report
[J]. Reactions Weekly, 2021, 1836 (1) : 642 - 642
[9] NivolumabBilateral vocal cord paralysis, immune-related hepatitis, and immune-related colitis: case report
[J]. Reactions Weekly, 2021, 1863 (1) : 275 - 275
[10] Bevacizumab/ipilimumab/pembrolizumabBrain haemorrhage, immune-related hypophysitis and immune-related hepatitis: case report
[J]. Reactions Weekly, 2017, 1633 (1) : 125 - 125

← 1 2 3 4 5 →